Table 2 Double-blind baseline demographics and clinical characteristics
Study active arms | Study placebo arms | |||
|---|---|---|---|---|
PP | Paliperidone ER | PP placebo | Paliperidone ER placebo | |
(n= 193) | (n= 104) | (n= 192) | (n= 101) | |
Age in years, mean (SD) | 38.6 (11.4) | 39.0 (10.7) | 39.2 (10.8) | 37.5 (10.4) |
Sex, n (%) | ||||
Male | 104 (53.9) | 58 (55.8) | 104 (54.2) | 63 (62.4) |
Female | 89 (46.1) | 46 (44.2) | 88 (45.8) | 38 (37.6) |
Race, n (%) | ||||
Caucasian | 124 (64.3) | 62 (59.6) | 126 (65.6) | 61 (60.4) |
Black | 36 (18.7) | 8 (7.7) | 35 (18.2) | 9 (8.9) |
Asian | 30 (15.5) | 3 (2.9) | 27 (14.1) | 0 |
Other | 3 (1.6) | 31 (29.8)a | 4 (2.1) | 31 (30.7)a |
Age at diagnosis in years, mean (SD) | 26.3 (9.2) | 27.1 (9.2) | 28.2 (8.9) | 25.8 (9.4) |
Baseline PANSS total score, mean (SD) | 50.8 (11.0) | 51.0 (11.4) | 51.9 (11.1) | 53.4 (10.6) |
Baseline CGI-S score, n (%) | ||||
Not ill | 11 (5.7) | 6 (5.8) | 11 (5.7) | 5 (5.0) |
Very mildly ill | 69 (35.8) | 38 (36.5) | 77 (40.1) | 33 (32.7) |
Mildly ill | 92 (47.7) | 49 (47.1) | 81 (42.2) | 54 (53.5) |
Moderately ill | 21 (10.9) | 11 (10.6) | 23 (12.0) | 9 (8.9) |
Previous hospitalisations for psychosis, mean (SD) | 2.6 (1.2)a | 2.9 (1.2)b | 2.7 (1.2)a | 2.9 (1.2)c |